Clinical trials
Completed Tuberculosis trials in Peru
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2 |
| Janssen Infectious Diseases BVBA | 2 |
| Médecins Sans Frontières, France | 2 |
| Centers for Disease Control and Prevention | 1 |
| Harvard University Faculty of Medicine | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 |
| Universidad Peruana Cayetano Heredia | 1 |
| Universitas Padjadjaran | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tuberculosis | 15 |
| Tuberculosis, Pulmonary | 7 |
| Tuberculosis, Multidrug-Resistant | 6 |
| HIV Infections | 5 |
| Bacterial Infections | 2 |
| Extensively Drug-Resistant Tuberculosis | 2 |
| Diabetes Mellitus | 1 |
| Gram-Positive Bacterial Infections | 1 |
| Mycobacterium Infections | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.